MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. - Wikidata - wikimedia - TriplyDB

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

http://www.wikidata.org/entity/Q34565346

about

Novel non invasive diagnostic strategies in bladder cancer Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer.Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis Meta-analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk.Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as a Molecular Insight towards Personalized Medicine.P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis.Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.Investigation of the association between the MDM2 T309G polymorphism and gastric cancer.Association of p53 and mdm2 in the development and progression of non-small cell lung cancer.

P2860

Q26752188-AFFA95CD-D8D9-4AF2-8CD7-7EE4DE8A8AB0 Q35854027-E8970FED-8F24-4EC3-BA2E-D5445225F860 Q37205283-C23358A0-1613-45F5-9D27-4030F7BEC636 Q37565358-F5849322-C580-4CF2-8FE8-FE72D3AB35F5 Q41465239-734AE724-3F60-4D67-BC09-58794E86AC59 Q44176695-DE8C678A-3CD1-47E6-A637-02DF6BB0EFC8 Q44416876-541C3F09-6256-4210-98B3-AB12A9815CBF Q47157603-81B332E9-B88B-4580-BC74-5725E1C20E86 Q53620032-2E4C2966-154A-4734-B25D-C8C8720D5B98

P2860

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

http://www.wikidata.org/entity/Q34565346

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@ast

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@en

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@nl

type

label

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@ast

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@en

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@nl

prefLabel

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@ast

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@en

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@nl

P1433

Q34565346-B0F41333-69A2-4618-9DAF-150130C9367F

P1476

Q34565346-3BD870D8-AF74-45A4-8C15-073902141E43

P2093

Q34565346-189DB969-E7E9-40BB-B04E-15B9D9976173

Q34565346-455A92F0-3D4B-4B54-B623-514BFFC618A9

Q34565346-4D11AA8C-4712-459C-958D-271496A3FA16

Q34565346-5AC96C0A-E314-4D31-8A06-A41AEC69E584

Q34565346-D9D2B28A-A357-46E3-B05A-A743BA78E276

P2860

Q34565346-005C6A7D-8460-43B1-99DA-EFD582CB76EC

Q34565346-09180AC2-98BC-493E-BC7F-5DB543EA08B5

Q34565346-0F25D081-F38E-4739-9928-50EA3B33C2F9

Q34565346-119B38FC-88FF-43A3-B7AB-99AA102F1B3A

Q34565346-208D47E1-DCEC-453B-9317-C4E45D78EAF2

Q34565346-2320CE56-F862-4D44-BD1C-CA20C043B6C0

Q34565346-26EB0E6E-088F-4AA0-B36D-EF5201F3D279

Q34565346-27D33B93-AEC2-437F-B9D0-23BAAA4D3DF1

Q34565346-383E8E6A-1EDE-40FB-9721-B2FDB9ACE494

Q34565346-3F1055B9-221D-4E6D-AA48-3BA6DCA039CC

P2888

Q34565346-C3C4786F-C55F-4027-9FCC-A3C38661CCC8

P304

Q34565346-0810F0A4-3EB5-437B-96F0-078F3DA1FB9D

P31

Q34565346-48CC7A19-01A9-4BCD-99CF-15EC541CBFED

P356

Q34565346-743D0848-E54A-4540-AAAA-5F7FA86EF733

P478

Q34565346-89DF76C5-B998-4809-9F3B-82CE83BDE315

P577

Q34565346-87FB52B4-0A39-42B9-A589-CD40D891DDC1

P5875

Q34565346-9F7D89C5-A18D-45D8-8D8D-DF2A7A9D8C49

P6179

Q34565346-51EEE514-F95E-44F2-B991-57BF3CD0B1C0

P698

Q34565346-5FDAD260-92D2-410D-87FF-BEA1E79B5BF3

P932

Q34565346-B61E17AF-B6E0-44B1-ACD6-4B586D193680

P356

P1433

P1476

MDM2 SNP309 promoter polymorph ...... ry bladder carcinoma stage T1.

@en

P2093

Hans Olsson

http://www.w3.org/2001/XMLSchema#string

Johan Rosell

http://www.w3.org/2001/XMLSchema#string

Per Hultman

http://www.w3.org/2001/XMLSchema#string

Peter Söderkvist

http://www.w3.org/2001/XMLSchema#string

Staffan Jahnson

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

The MDM2-p53 interaction.

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.

Recent advances in p53 research and cancer treatment

The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck

The RP-Mdm2-p53 pathway and tumorigenesis

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.

Immunohistochemical evaluation of cell cycle regulators: impact on predicting prognosis in stage t1 urinary bladder cancer.

Lymphovascular invasion as a prognostic tool for advanced bladder cancer.

P2888

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2490-13-5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235378024

http://www.w3.org/2001/XMLSchema#string

P6179

1014636117

http://www.w3.org/2001/XMLSchema#string

P698

23356517

http://www.w3.org/2001/XMLSchema#string

P932

3574032

http://www.w3.org/2001/XMLSchema#string